MedPath

A clinical trial investigating the effect of Lanreotide on the reduction of output in patients with high-ouput enterocutaneous fistula or high-output enterostomy

Recruiting
Conditions
enterocutaneous fistula, enterocutane fistels, Lanreotide, output reduction, output reductie
Registration Number
NL-OMON25162
Lead Sponsor
Academic Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
40
Inclusion Criteria

aged 18 years or older

- confirmed diagnosis and localisation of fistula origin (CT/fistulography/enteral contrast MRI)

Exclusion Criteria

- recent treatment with short acting somatostatin analogues (>1 week consecutive treatment in past 3 months)

- High ouput fistula after pancreatitis or pancreatic surgery

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The number of responders in week 8. Definition of a responder is a<br>decrease in output of &#8805;25% at week 8 compared with baseline output at randomisation.
Secondary Outcome Measures
NameTimeMethod
- days to full oral or enteral nutrition<br /><br>- change in amount of TPN/week<br /><br>-time to reach the maximal effect in fistula output.<br /><br>- Percent reduction in total fistula output from pre randomisation<br /><br>- no. of days in hospital<br /><br>- changes in needed iv fluid (mL)<br />
© Copyright 2025. All Rights Reserved by MedPath